Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.002 | 0.1029 | 0.3434 |
Schistosoma mansoni | lamin | 0.0031 | 0.2997 | 0.2194 |
Echinococcus multilocularis | musashi | 0.0031 | 0.2997 | 0.2925 |
Schistosoma mansoni | intermediate filament proteins | 0.0031 | 0.2997 | 0.2194 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0399 | 0.1333 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.1029 | 0.5 |
Onchocerca volvulus | 0.0031 | 0.2997 | 0.5 | |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.007 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0031 | 0.2997 | 0.2925 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.002 | 0.1029 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.1029 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.002 | 0.1029 | 0.5 |
Schistosoma mansoni | lamin | 0.0031 | 0.2997 | 0.2194 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.007 | 1 | 1 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.007 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.002 | 0.1029 | 0.5 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.007 | 1 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.002 | 0.1029 | 0.5 |
Brugia malayi | intermediate filament protein | 0.0031 | 0.2997 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0031 | 0.2997 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.002 | 0.1029 | 0.0937 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.1029 | 0.5 |
Echinococcus multilocularis | lamin | 0.0031 | 0.2997 | 0.2925 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0.1029 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.007 | 1 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.007 | 1 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0031 | 0.2997 | 0.2925 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.1029 | 0.5 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.007 | 1 | 1 |
Onchocerca volvulus | 0.0031 | 0.2997 | 0.5 | |
Schistosoma mansoni | aldehyde dehydrogenase | 0.007 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0031 | 0.2997 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0031 | 0.2997 | 0.2925 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.002 | 0.1029 | 0.0937 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.002 | 0.1029 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0102 | 0.0342 |
Loa Loa (eye worm) | hypothetical protein | 0.0031 | 0.2895 | 0.9658 |
Loa Loa (eye worm) | hypothetical protein | 0.0031 | 0.2997 | 1 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.002 | 0.1029 | 0.2424 |
Echinococcus granulosus | lamin | 0.0031 | 0.2997 | 0.2925 |
Loa Loa (eye worm) | intermediate filament protein | 0.0031 | 0.2997 | 1 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.007 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0.1029 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 3 uM | Antituberculosis activity against Mycobacterium tuberculosis H37Rv under aerobic conditions by microplate alamar blue assay | ChEMBL. | 21846109 |
MIC (functional) | = 27 uM | Antituberculosis activity against Mycobacterium tuberculosis H37Rv under anaerobic conditions by fluorescence based low-oxygen-recovery assay | ChEMBL. | 21846109 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.